

REMARKS

Claims 1, 59, and 65-67 are pending in the present application. By the present communication, no claims have been added or canceled, and claims 59 and 67 have been amended to define Applicants' invention with greater particularity. Support for the amended claims may be found within the specification and claims as filed. Accordingly, upon entry of the present amendment, claims 1, 59, and 65-67 will be under consideration.

Objections to the Claims

Applicants respectfully traverse the objection of claim 67 as allegedly containing a typographical error. Without acquiescing to the reasoning offered by the Office, and in order to expedite prosecution of the instant application, Applicants have amended claim 67 to depend from claim 66. Withdrawal of the objection is respectfully requested.

Rejections under 35 U.S.C. §112, First Paragraph

Applicants respectfully traverse the rejection of claims 59 and 65-67 under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement. Specifically, the Office Action alleges that the specification does not reasonably provide enablement for a composition comprising a therapeutically effective amount of a substantially pure hKCa3/KCNN3 polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2 and a pharmaceutically acceptable carrier. Without acquiescing to the reasoning offered by the Office, and in order to expedite prosecution of the instant application, Applicants have amended claim 59 to remove the term "a therapeutically effective amount of," as suggested by the Examiner. Withdrawal of the rejection is respectfully requested.

In re Application of:
Chandy et al.
Application No.: 10/722,189
Filed: November 24, 2003
Page 4

PATENT
Attorney Docket No.: UCII120-4


Conclusion

In view of the amendments and above remarks, it is submitted that the claims are in condition for allowance, and a notice to that effect is respectfully requested. The Examiner is invited to contact Applicant's undersigned representative if there are any questions relating to this application.

No fee is believed to be due in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any fees that may be required by this paper, or credit any overpayment to Deposit Account 07-1896 referencing the above-identified attorney docket number.

Respectfully submitted,

Date: November 15, 2007



Antony M. Novom, J.D.
Registration No. 45,517
Telephone: (858) 638-6641
Facsimile: (858) 677-1465

DLA PIPER US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213